cyprotex
the ADME Tox specialists
home > in vitro toxicology > cytotoxicity screening panel

High Content Toxicology: Cytotoxicity Screening Panel

  • Drug toxicity is often a combination of multiple mechanisms. A single experimental approach is unlikely to capture the complexity involved in cellular toxicity.
  • High Content Screening uses automated fluorescence imaging to simultaneously analyse multi-parametric indicators of cellular toxicity. It can detect general cell death and/or mechanisms of cell death within the same cell population within the same a well, and it can cover a wide spectrum of cytopathological changes.
  • Cyprotox have the most advanced High Content Screening equipment available, including four Thermo Scientific Cellomics ArrayScan® VTI’s and a Thermo Scientific Cellomics ToxInsight.
  • Cyprotox offer a cytotoxicity panel to evaluate key toxicity markers including cell number, nuclear condensation, total nuclear intensity, cell permeability, mitochondrial membrane potential and cytochrome c release.
 
 
‘Assays with multiple parameters for key, multiple, and different features, such as in high content screening (HCS), are more predictive because they cover a wider spectrum of effects.’
1 O’Brien P and Haskins JR (2007) High Content Screening: A Powerful Approach to Systems Cell Biology and Drug Discovery Ed. Taylor et al.; 415-425
Protocol +
Data +
References

1 O’Brien P and Haskins JR (2007) High Content Screening: A Powerful Approach to Systems Cell Biology and Drug Discovery Ed. Taylor et al.; 415-425
2 Hoffman AF and Garippa RJ (2007) High Content Screening: A Powerful Approach to Systems Cell Biology and Drug Discovery Ed. Taylor et al.; 19-31

 
cytotoxicity screening panel

Download a copy of the product sheet

careerscontactlegalprivacy
This website was last updated
on 15th May 2012
This website is intended to assist investors, industry participants, customers and employees to understand Cyprotex’s global operations and ambitions.
Certain information and detail is disclosed in the interest of compliance of AIM Rule 26.